SLS - ガリ―ナ・バイオファ―マ (SELLAS Life Sciences Group Inc. ) ガリ―ナ・バイオファ―マ

 SLSのチャート


 SLSの企業情報

symbol SLS
会社名 SELLAS Life Sciences Group Inc (ガリ―ナ・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アールエックスアイ・ファーマシューティカルズ(RXi Pharmaceuticals Corporation)はリボ核酸(RNA)干渉(RNAi)を標的とした技術と免疫療法技術を利用して、アンメットメディカルニーズに対処する治療法の発見・開発・商用化に従事するバイオ企業。同社は種々の癌の治療のために、主要な製品候補「NeuVaxtm」を含むペプチドベースの免疫療法製品を活用する癌の治療法、及び標的となる疾患関連遺伝子を発現、或いは発現抑制する自然発生的な細胞メカニズムのRNA干渉(RNAi)に基づいた治療法を追求する。同社の主要な製品は「Herceptin」に不適格の初・中期HER2陽性乳癌患者において乳癌の再発を減少させるペプチドベースの免疫療法「NeuVax」。同社のRNAi製品「RXI-109」は結合組織成長因子を標的とする皮膚抗瘢痕治療法。平成23年4月13日、同社は民間のバイオ企業Apthera Inc. (Apthera)を買収した。   ガリ―ナ・バイオファ―マは、米国のバイオ医薬品企業。癌性疼痛の持続的疼痛管理時の急激な痛み(突出痛)に対して、舌下投与による有効成分フェンタニルの速やかな吸収と鎮痛効果を主薬効とする治療剤アブストラルや、原発性癌の免疫療法の癌の再発の予防のためにNeuVaxを開発。また、婦人科癌、卵巣癌および子宮内膜腺癌で臨床試験の段階の製品もある。   SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, NPS, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.
本社所在地 15 West 38th Street 10th Floor New York NY 10018 USA
代表者氏名 Angelos M. Stergiou Angelos M. Stergiou
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 917-438-4353
設立年月日 38808
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 11人
url www.sellaslife.com
nasdaq_url https://www.nasdaq.com/symbol/sls
adr_tso
EBITDA EBITDA(百万ドル) -25.27600
終値(lastsale) 1.2864
時価総額(marketcap) 25178151.4752
時価総額 時価総額(百万ドル) 30.53321
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 36.96321
当期純利益 当期純利益(百万ドル) -33.53800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Sellas Life Sciences Group Inc revenues was not reported. Net loss applicable to common stockholders increased 76% to $18.5M. Higher net loss reflects General and administrative - Balancing v increase from $3.8M to $8.7M (expense) Change in fair value of the contingent p increase from $0K to $3.9M (expense) Gain/Loss on Derivatives - Hedging increase from $0K to $727K (expense).

 SLSのテクニカル分析


 SLSのニュース

   Sellas Life Sciences gets China regulator nod to start trial of immunotherapy 3D189  2022/04/06 15:40:23 Seeking Alpha
Cancer therapies developer Sellas Life Sciences (SLS) announced that an application to start a clinical trial in China for Sellas'' lead product candidate 3D189 to treat blood cancers…
   The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck''s Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study  2022/04/01 13:08:28 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Reata Completes Regulatory Filing For Omaveloxolone As Treatment Option For Neurodegenerative Movement Disorder Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) said it has completed filing the rolling submission of a new drug application to the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreich''s ataxia. The FDA has granted Fast Track Designation and Orphan Drug Designation to omaveloxolone for the treatment of Friedreich''s ataxia. The stock was adding 2.14% to $33.46 in premarket trading. Eisai Buys Healthcare-Related Digital Software Service Provider Arteryex Eisai Co. Ltd. (OTC: ESALY ) announced that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares.
   SELLAS Life Sciences Stock Plunges After $25M Capital Raise Via Equity, In-Licenses Cancer-Focused CDK9 Inhibitor  2022/04/01 12:41:38 Benzinga
GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc (NASDAQ: SLS ) across all therapeutic and diagnostic uses worldwide outside of Greater China (mainland China, Hong Kong, Macau, and Taiwan). GFH009 is a highly selective small-molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GFH009 is currently in Phase 1 trials in the U.S. and China. After completing the Phase 1 trial and achieving a maximum tolerated dose, SELLAS plans to commence … Full story available on Benzinga.com
   BBIG, NAOV and ISPO among pre market losers  2022/04/01 12:41:16 Seeking Alpha
SELLAS Life Sciences SLS -39% plunged 24% on $25M stock offering.ARCA biopharma ABIO -22% fails to meet key goal in mid-stage trial for COVID-19 therapy.Redwire RDW -18% on Q4…
   SELLAS Life Sciences plunged 24% on $25M stock offering  2022/04/01 10:05:48 Seeking Alpha
SELLAS Life Sciences (SLS) plunged 23.7% premarket after it priced its earlier announced underwritten public offering of 4.63M shares and accompanying warrants at combined public…
   Overview of Different Indicators: Evolve Transition Infrastructure LP (AMEX:SNMP), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)  2021/08/01 21:41:02 Stock Equity
Evolve Transition Infrastructure LP (SNMP) with the stream of -10.27% also noticed, India SELLAS Life Sciences Group, Inc. (SLS) encountered a rapid change of -1.50% in the last hour of The post Overview of Different Indicators: Evolve Transition Infrastructure LP (AMEX:SNMP), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) appeared first on Stocks Equity .
   May This Data Fuel Up Investors Confidence? Advanced Micro Devices, Inc. (NASDAQ:AMD), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)  2021/07/30 23:45:03 Stock Equity
Advanced Micro Devices, Inc. (NASDAQ:AMD) with the stream of 3.15% also noticed, India SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) encountered a rapid change of -1.50% in the last hour of The post May This Data Fuel Up Investors Confidence? Advanced Micro Devices, Inc. (NASDAQ:AMD), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) appeared first on Stocks Equity .
   SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021  2021/07/28 12:30:00 Intrado Digital Media
Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee
   Most Active Stock Now: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), BIO-key International, Inc. (NASDAQ:BKYI)  2021/07/22 22:35:35 Stock Equity
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) with the stream of -4.19% also noticed, India BIO-key International, Inc. (NASDAQ:BKYI) encountered a rapid change of 2.12% in the last hour of Thursdays The post Most Active Stock Now: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), BIO-key International, Inc. (NASDAQ:BKYI) appeared first on Stocks Equity .
   Up to Date Stock in Review: Nokia Corporation (NYSE:NOK), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)  2021/07/15 21:09:16 Stock Equity
Nokia Corporation (NOK) with the stream of -2.05% also noticed, India SELLAS Life Sciences Group, Inc. (SLS) encountered a rapid change of 2.38% in the last hour of Thursdays trading The post Up to Date Stock in Review: Nokia Corporation (NYSE:NOK), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) appeared first on Stocks Equity .
   Hooky Stock: ON Semiconductor Corporation (NASDAQ:ON), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)  2021/07/08 02:26:16 Stock Equity
ON Semiconductor Corporation (NASDAQ:ON) with the stream of -2.42% also noticed, India SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) encountered a rapid change of -1.25% in the last hour of Wednesday’s … The post Hooky Stock: ON Semiconductor Corporation (NASDAQ:ON), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) appeared first on Stocks Equity .
   :   2021/07/07 15:19:30 NewsIt
SELLAS Life Sciences Group, , - - , : galinpepimut-S (GPS) To : NewsIT .
   Active Stock to Observe: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), 22nd Century Group, Inc. (AMEX:XXII)  2021/07/07 00:15:20 Stock Equity
SELLAS Life Sciences Group, Inc. (SLS) with the stream of -0.31% also noticed, India 22nd Century Group, Inc. (XXII) encountered a rapid change of -1.51% in the last hour of The post Active Stock to Observe: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), 22nd Century Group, Inc. (AMEX:XXII) appeared first on Stocks Equity .
   Buy or Sell? What Analysts Recommends: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), GEE Group, Inc. (AMEX:JOB)  2021/07/06 02:29:28 Stock Equity
SELLAS Life Sciences Group, Inc. (SLS) with the stream of -2.47% also noticed, India GEE Group, Inc. (JOB) encountered a rapid change of 5.43% in the last hour of Mondays The post Buy or Sell? What Analysts Recommends: SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), GEE Group, Inc. (AMEX:JOB) appeared first on Stocks Equity .
   3   2021/07/05 07:29:10 Zougla
SELLAS Life Sciences Group (NASDAQ: SLS), ,

 関連キーワード  (医薬品 米国株 ガリ―ナ・バイオファ―マ SLS SELLAS Life Sciences Group Inc. )

 twitter  (公式ツイッターやCEOツイッターなど)